Compass Therapeutics Discloses FY Results with Net Loss of $42.5 Million and 27% Rise in R&D Expenses

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.